SLC5A2 and diabetes mellitus: Additionally, combination therapies involving antidiabetic drugs, such as GLP-1 agonists (https://classic.clinicaltrials.gov/ct2/show/NCT03987074, accessed on 19 July 2023) and SGLT2 inhibitors (https://classic.clinicaltrials.gov/ct2/show/NCT04065841, accessed on 19 July 2023), are being investigated for their potential to enhance outcomes related to both liver health and diabetes.